Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Sunitinib Malate
... CAGR of 9.6% over the analysis period 2024-2030. Above 99% Purity Sunitinib Malate, one of the segments analyzed in the report, is expected to record a 10.5% CAGR and reach US$120.6 Million by the end ... Read More
-
Nano-Magnetic Devices
... CAGR of 5.4% over the analysis period 2024-2030. Nano-Magnetic Sensors, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$12.8 Billion by the end of the analysis ... Read More
-
Cervical Cancer Endoscopic Devices
... 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Optical Colposcopes, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$668.1 Million by the ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Genomics in Cancer Care
... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomics Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
Immunomodulators
... 5.7% over the analysis period 2024-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$209.8 Million by the end of the analysis period. Growth in ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Tumor / Cancer Markers
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.4% CAGR The Tumor / Cancer Markers market ... Read More
-
Microwave Ablation
... CAGR of 13.2% over the analysis period 2024-2030. Liver Cancer Application, one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$215.5 Million by the end of the ... Read More
-
Cancer / Tumor Profiling
... 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Immunoassays Technology, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$6.7 Billion by the ... Read More
-
Endometrial Cancer Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Basal Cell Carcinoma Treatment
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$7.6 Billion by the ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$12.1 Billion by the end of ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia Therapeutics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of ... Read More
-
Metastatic Bone Disease
... at a CAGR of 6.7% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$12.3 Billion by the end of the ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Breast Cancer Liquid Biopsy
... 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Liquid Biopsy Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.4% CAGR and reach US$819.3 Million ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
Research Assistance
